PDCD1 and Miyoshi myopathy: By contrast, currently, the outcome of checkpoint blockade with PD-1/PD-L1 inhibitors alone is unsatisfactory in MM, compared with HL or solid tumors due to the reduced immune dysfunction in MM [200].